Cohort Study of Pancreatic Cancer Risk

  • STATUS
    Recruiting
  • End date
    Dec 28, 2026
  • participants needed
    2000
  • sponsor
    Mayo Clinic
Updated on 19 February 2024

Summary

This study is designed to develop a cohort of individuals without pancreatic cancer, but who are at increased risk of developing it due to family history or genetic predisposition. These high-risk individuals will be asked to provide baseline and annual (serial) follow-up blood samples for the duration of the study funding. Mayo Clinic is part of a national Pancreatic Cancer Detection Consortium (PCDC)[1] which aims to establish a high-risk cohort with the goal of validating blood biomarkers (discovered/developed outside of this protocol) using the samples collected serially (annually) that predict or detect pancreatic cancer prior to clinical diagnosis.

Description

The high mortality rate of pancreatic cancer is primarily due to the advanced stage at diagnosis in the majority of cases. The five-year survival rate for this cancer is only 9%, the poorest survival rate of any major cancer, making pancreatic cancer the third leading cancer killer that affects both men and women in the United States. Five-year survival can be improved if the cancer is detected earlier.[2] It is thus important to apply cancer genetics, risk assessment, and early detection that can identify a population of high-risk individuals who can benefit from early detection.

A key strategy for effective early detection research in pancreatic cancer is to identify and build longitudinal high-risk cohorts and maintain data from baseline to follow up, and biobanking of repeated (annual) non-invasive biospecimen collections. The research to be performed would compare samples of participants who develop cancer over time compared to those who do not. Tests that would be applied to the biospecimen collections would use subsets of participants in designs that would provide the maximum amount of information about the performance of the assays in predicting who has cancer at an early stage [3,4].

The collection of biosamples and data for the family-based biobank resource/registry proposed here is partially funded by NCI funded U01 grants, through the PCDC [1]. At Mayo Clinic, NCI grant U01 CA210138 is the funding source. The PCDC is committed to developing a longitudinal cohort (registry) of individuals and family members currently without pancreatic cancer, but who are at high risk due to family history of pancreatic cancer or predisposition gene mutation status. High-risk individuals will be recruited at each site, and biospecimens will be logged, stored, administered, and studied by consensus protocols of members of the PCDC. The maintenance of protocols will be maintained by the PCDC Administrative Core at Mayo Clinic. The PCDC cohort will require a long-term investment and will be most successful with multiple contributing sites.

Details
Condition Familial Pancreatic Cancer
Age 18-100 years
Clinical Study IdentifierNCT04247503
SponsorMayo Clinic
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

b'An individual who has previously consented to the Biospecimen Resource for Pancreas'
b'Research (Substudy #2 Family Studies) - IRB 355-06'
b'Individual who does not have a personal history of pancreatic cancer and meets one of'
b'the following:'
b'Has relatives in family that contains pancreatic cancer, and carries a known'
b'germline mutation in APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6,'
b'PALB2, PMS2, STK11, or TP53.'
b'OR'
b'Is a first- or second-degree blood relative of an individual with a diagnosis of'
b'pancreatic ductal adenocarcinoma (PDAC) and this PDAC patient has a germline'
b'mutation in APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2,'
b'STK11, or TP53.'
b'OR'
b'Is a first- or second-degree blood relative of an individual with a germline'
b'mutation in one of these genes and where the mutation carrier is also a'
b'first-degree relative to a PDAC case.'
b'OR'
b'Is a blood relative to a PDAC patient in a family that contains three blood'
b'relatives (all maternal side or all paternal side) with PDAC.'
b'Age'
b'50 or older, OR'
b'Or within 10 years of the age of diagnosis of the youngest PDAC blood relative.'
b'Individual with a valid United States mailing address. -'

Exclusion Criteria

b'Individual who has a personal history of PDAC'
b'Individual who has received a bone marrow transplant, who has had a blood transfusion'
b'within the last 7 days, or who has an active hematologic malignancy (i.e., leukemia or'
b'lymphoma).'
b'Individual who is unable to sign the informed consent because of mental incompetency'
b'or psychiatric illness'
b'Individual who is non-English speaking'
b'Individual who is a prison inmate -'
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.